TYMP Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• The TYMP gene encodes thymidine phosphorylase, a homodimeric enzyme crucial for pyrimidine salvage and maintaining balanced deoxyribonucleoside triphosphate pools, particularly in mitochondria. Loss-of-function mutations lead to Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE), characterized by severe gastrointestinal dysmotility, cachexia, ptosis, ophthalmoplegia, and peripheral neuropathy.
• Beyond its metabolic role, TYMP functions as a pleiotropic cytokine (PD-ECGF) promoting angiogenesis, cell survival, and inflammation, and is implicated in tumor progression, chemoresistance, and immune evasion, with elevated expression in numerous solid tumors.
• TYMP is essential for the enzymatic activation of capecitabine, a prodrug for 5-fluorouracil; thus, TYMP expression levels are a critical determinant of patient response to fluoropyrimidine-based chemotherapy, with specific polymorphisms influencing treatment outcomes.
• Diagnostic confirmation of MNGIE involves elevated plasma thymidine and 2′-deoxyuridine levels (>3-fold) and reduced peripheral blood leukocyte thymidine phosphorylase activity (<10% of normal), alongside genetic identification of biallelic TYMP mutations.
• Therapeutic strategies for MNGIE include erythrocyte-encapsulated TP (EE-TP) for enzyme replacement, gene therapy using AAV vectors targeting the liver or HSCs, and allogeneic hematopoietic stem cell transplantation (HSCT), while TYMP inhibitors are being explored for cancer and COVID-19-associated thrombosis.

Executive Summary & Key Metadata

The TYMP gene (thymidine phosphorylase; previously designated ECGF1, platelet-derived endothelial cell growth factor, or PD-ECGF) encodes a 482-amino-acid homodimeric enzyme that catalyzes the reversible phosphorolysis of thymidine and 2′-deoxyuridine to their respective nucleobases and 2-deoxyribose-1-phosphate [1, 2, 3]. This reaction is rate-limiting in the pyrimidine salvage pathway and is essential for maintaining balanced deoxyribonucleoside triphosphate (dNTP) pools, particularly within the mitochondrial compartment [4]. Loss-of-function mutations in TYMP cause Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE; OMIM #603041), an ultra-rare autosomal recessive disorder characterized by severe gastrointestinal dysmotility, cachexia, ptosis, external ophthalmoplegia, peripheral neuropathy, and diffuse leukoencephalopathy [1, 5, 6, 7]. Beyond its canonical metabolic role, TYMP functions as a pleiotropic cytokine, originally identified as platelet-derived endothelial cell growth factor, promoting angiogenesis, cell survival, and inflammation [2, 8, 9]. Elevated TYMP expression is a hallmark of numerous solid tumors and correlates with chemoresistance, immune evasion, and poor prognosis [1, 2, 3]. Conversely, TYMP is required for the enzymatic activation of the prodrug capecitabine, making its expression a critical determinant of fluoropyrimidine-based chemotherapy response [4, 5, 6, 7]. This reference manual provides an exhaustive, publication-grade analysis of TYMP genomic architecture, structural biology, signaling networks, pathogenic mutations, pharmacogenomics, and therapeutic targeting.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Gene Structure

The TYMP gene is located on the long arm of chromosome 22 at band q13.33 (GRCh38 coordinates: chr22:50,968,692–50,972,039; minus strand orientation) [2, 8]. The gene spans approximately 3.35 kilobases of genomic DNA and contains 10 exons and 9 introns, with a coding sequence of 1,446 nucleotides that translates into a 482-amino-acid protein [3, 8]. The TYMP locus is embedded within a gene-dense region of chromosome 22, adjacent to the SCO2 gene (cytochrome c oxidase assembly factor) and the TANGO2 gene (transport and Golgi organization 2 homolog). This genomic proximity has clinical relevance: large copy-number variations (CNVs) can simultaneously disrupt TYMP and neighboring genes, producing complex mitochondrial phenotypes [9]. Vondráčková et al. reported a patient with combined point mutations in TYMP and SCO2 alongside a large deletion, illustrating the potential for contiguous gene syndromes at this locus [9].

1.2 Promoter Architecture and Transcriptional Regulation

The TYMP promoter region is GC-rich and lacks a canonical TATA box, a feature typical of housekeeping genes. Instead, transcription is driven by multiple Sp1/Sp3 binding sites and a MAZ (MYC-associated zinc finger protein) consensus motif [1, 2]. The transcription factor MAZ has been shown to activate TYMP transcription in clear cell renal cell carcinoma (ccRCC) by binding to a hypomethylated promoter region, thereby upregulating TYMP expression in tumor tissue [1]. Conversely, DNA methylation of the TYMP promoter silences gene expression; demethylating agents such as 5-azacytidine can restore TYMP expression and sensitize colorectal cancer cells to 5-fluorouracil (5-FU) [3]. This epigenetic regulation is clinically significant because TYMP expression levels directly influence the efficacy of capecitabine and 5-FU-based chemotherapy [3, 4].

Additional transcription factors implicated in TYMP regulation include HIF-1α (hypoxia-inducible factor 1 alpha), which binds to hypoxia-response elements in the TYMP promoter and upregulates expression under hypoxic conditions, a common feature of the tumor microenvironment [4, 8]. The Sp1 inhibitor mithramycin A has been shown to downregulate TYMP expression in rheumatoid arthritis fibroblast-like synoviocytes, confirming the importance of Sp1 in basal TYMP transcription [2].

1.3 Enhancer Elements and Chromatin State

Chromatin immunoprecipitation (ChIP)-seq data from ENCODE reveal that the TYMP promoter is marked by H3K4me3 (active promoter) and H3K27ac (active enhancer) histone modifications in most cell types, consistent with its ubiquitous expression. A putative enhancer element located approximately 2 kb upstream of the transcription start site (TSS) contains binding sites for CEBPB and FOXA1, which may modulate tissue-specific expression in the liver and gastrointestinal tract [1, 8]. In ccRCC, the TYMP promoter is hypomethylated relative to normal kidney tissue, leading to constitutive activation; this epigenetic switch is associated with poor prognosis and immune infiltration [1].

1.4 Alternative Splicing and Isoforms

The TYMP gene undergoes alternative splicing that produces at least two transcript variants. The canonical transcript (NM_001953.5) encodes the full-length 482-amino-acid protein. A second transcript variant (NM_001113755.2) lacks exon 2, resulting in a shorter protein isoform of 456 amino acids that retains catalytic activity but exhibits altered subcellular localization [8]. The biological significance of this isoform is not fully characterized, but it may contribute to tissue-specific regulation of thymidine phosphorylase activity. Additionally, a nonstop mutation (c.1446A>G) that eliminates the native stop codon has been described in a MNGIE patient; this mutation does not trigger nonstop mRNA decay, resulting in a C-terminally extended protein with residual but severely impaired catalytic activity [5].

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Sequence and Domain Organization

Human thymidine phosphorylase (TP) is a 482-amino-acid protein with a molecular mass of approximately 50 kDa per monomer; the functional enzyme exists as a homodimer with a total molecular mass of ~100 kDa [6, 8]. The protein belongs to the NP-II family of nucleoside phosphorylases, which also includes uridine phosphorylase and purine nucleoside phosphorylase. Sequence alignment and structural studies have identified the following functional domains:

• N-terminal α/β domain (residues 1–190): Contains the dimerization interface and contributes to substrate specificity. This domain includes a pyrimidine nucleoside phosphorylase signature motif (residues 80–95) that is conserved across species [6].
• Central catalytic domain (residues 191–380): Harbors the active site, including the phosphate-binding loop (P-loop) and the nucleoside-binding pocket. Key catalytic residues include His116, Ser117, Lys143, Glu198, and Arg202 [6, 7].
• C-terminal α-helical domain (residues 381–482): Stabilizes the dimer interface and contains a regulatory loop that undergoes conformational changes upon substrate binding. Mutations in this region (e.g., p.Arg393_Val400dup) are associated with late-onset MNGIE and lipodystrophy [8].

2.2 Quaternary Structure and Active Site Architecture

The TYMP homodimer adopts a two-fold symmetric architecture in which the active site of each monomer is formed by residues from both subunits. The dimer interface buries approximately 3,200 Ų of solvent-accessible surface area and is stabilized by hydrophobic interactions, hydrogen bonds, and a network of salt bridges [6, 7]. The active site contains a phosphate-binding pocket that coordinates a phosphate ion, which acts as the nucleophile in the phosphorolysis reaction. The nucleoside-binding pocket is lined by aromatic residues (Phe210, Tyr213, Phe218) that stack with the thymine ring, while Glu198 forms a hydrogen bond with the 3′-hydroxyl group of the deoxyribose moiety [6, 7].

2.3 Catalytic Mechanism

The enzymatic reaction catalyzed by TP is:

Thymidine + Phosphate ⇌ Thymine + 2-Deoxyribose-1-Phosphate

The reaction proceeds via an SN1-like mechanism in which protonation of the thymine base by a conserved histidine residue (His116) facilitates cleavage of the N-glycosidic bond. The resulting oxocarbenium ion intermediate is stabilized by the phosphate anion, which then attacks the C1′ position of the deoxyribose to form 2-deoxyribose-1-phosphate [6, 7]. The equilibrium constant favors phosphorolysis over synthesis under physiological conditions, but the reverse reaction can occur when thymine and deoxyribose-1-phosphate concentrations are elevated. This bidirectional activity is exploited in gene therapy strategies that deliver TP to MNGIE patients to catabolize excess thymidine [1, 2, 9].

2.4 Structural Impact of Pathogenic Mutations

Molecular dynamics simulations of MNGIE-associated missense mutations have revealed that pathogenic variants cluster in the dimer interface and active site [6, 7]. For example, the common mutation p.Gly145Arg disrupts a conserved glycine in the P-loop, reducing phosphate binding affinity and catalytic efficiency by >95% [6]. The mutation p.Ser117Leu (a recurrent founder mutation in the Dominican Republic) directly contacts the thymine base and abolishes substrate binding [6]. In contrast, C-terminal mutations such as p.Arg393_Val400dup do not eliminate catalytic activity entirely but instead cause protein misfolding and accelerated degradation, leading to a milder, late-onset phenotype [8]. Computational docking studies of the novel mutation p.Thr151Pro demonstrated that this substitution introduces a kink in an α-helix adjacent to the active site, destabilizing the dimer and reducing thermal stability [7].

2.5 Interactive 3D Visualizer

Interactive 3D Protein Visualizer: Load TYMP (PDB: 1UOU)

The interactive visualizer allows users to explore the TYMP homodimer structure, highlighting the active site residues, dimer interface, and the spatial distribution of pathogenic mutations. Users can toggle between cartoon, surface, and electrostatic representations, and can overlay ClinVar variants to assess their structural context.

3. Cellular Signaling Pathways & Molecular Function

3.1 Canonical Metabolic Function: Pyrimidine Salvage

The primary biochemical role of TYMP is in the pyrimidine salvage pathway, where it catalyzes the phosphorolysis of thymidine and 2′-deoxyuridine [3, 8]. This reaction serves two critical functions:

1. Nucleotide pool homeostasis: By degrading excess thymidine and deoxyuridine, TP prevents the accumulation of these nucleosides, which would otherwise be phosphorylated by thymidine kinase 1 (TK1) and thymidine kinase 2 (TK2) to produce dTTP and dUTP. Imbalanced dNTP pools, particularly elevated dTTP, are mutagenic and inhibit mitochondrial DNA (mtDNA) replication [4].
2. Recycling of nucleobases: The thymine and uracil produced by TP can be reutilized via the salvage pathway or degraded further, contributing to overall nucleotide economy [8].

In MNGIE, TP deficiency leads to systemic accumulation of thymidine (up to 10-fold above normal) and 2′-deoxyuridine (up to 100-fold above normal) in plasma and tissues [3, 7]. These excess nucleosides are imported into mitochondria, where they are phosphorylated by TK2 to produce dTTP and dUTP. The resulting dTTP/dCTP imbalance and increased dUTP incorporation into mtDNA cause mtDNA depletion, multiple mtDNA deletions, and mitochondrial dysfunction [4]. Gonzalez-Vioque et al. demonstrated that limited dCTP availability, rather than dTTP excess per se, is the primary determinant of mtDNA depletion in MNGIE, as dUTP misincorporation and subsequent base-excision repair consume dCTP [4].

3.2 Non-Canonical Functions: Angiogenesis and Inflammation

TYMP was independently identified as platelet-derived endothelial cell growth factor (PD-ECGF) based on its ability to stimulate endothelial cell migration and angiogenesis in vitro and in vivo [2, 8]. The angiogenic activity of TP is mediated by its enzymatic product 2-deoxyribose-1-phosphate, which is dephosphorylated to 2-deoxyribose. 2-Deoxyribose is a reducing sugar that can act as a signaling molecule, promoting endothelial cell survival and migration through the PI3K/Akt and MAPK/ERK pathways [3, 8]. This metabolite also induces the expression of VEGF and MMP-9, amplifying the angiogenic response [8].

In addition to its role in angiogenesis, TYMP functions as an inflammatory mediator. TP is highly expressed in activated macrophages, platelets, and synovial fibroblasts, where it promotes the production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 [4, 9]. In rheumatoid arthritis, TP expression in fibroblast-like synoviocytes contributes to joint inflammation and pannus formation, and TP inhibition reduces disease severity in animal models [2, 9]. TP also participates in platelet activation and thrombosis: TP-deficient platelets exhibit reduced aggregation, and TP expression is upregulated in response to thrombin stimulation [9]. This pro-thrombotic function has implications for COVID-19, where SARS-CoV-2 spike protein enhances TP expression, contributing to the hypercoagulable state observed in severe disease [5].

3.3 TYMP in Immune Regulation and Cancer

In the tumor microenvironment, TYMP is expressed by both cancer cells and tumor-associated macrophages (TAMs) [1, 2, 3, 6]. TP expression in TAMs is associated with an M2-like immunosuppressive phenotype, characterized by high CD163 expression and secretion of anti-inflammatory cytokines [6]. TP promotes immune evasion by:

• Suppressing CD8+ T cell infiltration: High TYMP expression correlates with reduced CD8+ T cell density in ccRCC and other tumors [1, 7].
• Upregulating PD-L1: TP activity enhances PD-L1 expression on tumor cells via the 2-deoxyribose-mediated activation of the NF-κB pathway, leading to T cell exhaustion [3].
• Recruiting regulatory T cells (Tregs): TP-derived 2-deoxyribose promotes the differentiation of naïve T cells into FoxP3+ Tregs, further suppressing anti-tumor immunity [3].

A pan-cancer analysis by Yang et al. demonstrated that TYMP expression is elevated in most solid tumors and is associated with poor overall survival in ccRCC, hepatocellular carcinoma, and breast cancer, but with favorable prognosis in colorectal cancer (CRC) [2]. This context-dependent prognostic value reflects the dual role of TP in tumor progression and chemotherapy response [2, 5, 7].

3.4 Protein-Protein Interaction Networks

BioGRID and STRING databases list over 50 physical and functional interactors of TYMP. Key interactions include:

• Thymidine kinase 1 (TK1) and TK2: TP and TK enzymes function antagonistically in nucleotide metabolism; TK1 phosphorylates thymidine to dTMP, while TP degrades thymidine. The balance between these enzymes determines intracellular dTTP levels [8].
• HIF-1α: TP interacts with HIF-1α in a positive feedback loop; hypoxia induces TYMP transcription via HIF-1α, and TP-derived 2-deoxyribose stabilizes HIF-1α by inhibiting prolyl hydroxylases, creating a self-reinforcing pro-angiogenic signal [4, 8].
• p53: TP expression is negatively regulated by wild-type p53; loss of p53 in tumors leads to TYMP upregulation and increased chemoresistance [8].
• TREX1 (three-prime repair exonuclease 1): TP interacts with TREX1 in endothelial cells, where it modulates cytosolic DNA sensing and the RIG-I-like receptor pathway. TP deficiency attenuates RIG-I-induced endothelial dysfunction, suggesting a protective role in vascular inflammation [8].

3.5 Signaling Pathway Diagram

flowchart TD
    A["Hypoxia / HIF-1α"] -->|"Transcriptional activation"| B["TYMP gene"]
    C["MAZ / Sp1"] -->|"Transcriptional activation"| B
    D["Promoter methylation"] -->|"Transcriptional repression"| B
    B --> E["Thymidine phosphorylase protein"]
    E --> F["Thymidine + Pi"]
    F --> G["Thymine + 2-deoxyribose-1-P"]
    G --> H["2-deoxyribose"]
    H --> I["PI3K/Akt pathway"]
    H --> J["MAPK/ERK pathway"]
    I --> K["Endothelial cell migration"]
    J --> L["VEGF/MMP-9 upregulation"]
    K --> M["Angiogenesis"]
    L --> M
    E --> N["Nucleotide pool homeostasis"]
    N --> O["mtDNA replication fidelity"]
    O --> P["Mitochondrial function"]
    E --> Q["PD-L1 upregulation"]
    Q --> R["CD8+ T cell exhaustion"]
    E --> S["Treg recruitment"]
    S --> T["Immune evasion"]
    E --> U["Capecitabine activation"]
    U --> V["5-FU cytotoxic effect"]

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Mutation Spectrum in MNGIE

More than 100 pathogenic mutations in TYMP have been reported in the Human Gene Mutation Database (HGMD) and ClinVar, including missense, nonsense, frameshift, splice-site, and large deletion variants [5, 7, 9]. The majority of mutations are private (family-specific), but several recurrent mutations have been identified in specific populations:

• p.Ser117Leu (c.350C>T): A founder mutation in the Dominican Republic and Puerto Rico, accounting for ~20% of MNGIE alleles worldwide [9].
• p.Gly145Arg (c.433G>A): Recurrent in Italian and Spanish populations [1, 5].
• p.Glu198X (c.592G>T): A nonsense mutation reported in multiple European families [5].
• p.Arg202Gln (c.605G>A): Associated with late-onset MNGIE (>40 years) [2, 3].
• p.Arg393_Val400dup (c.1176_1199dup): An in-frame duplication in the C-terminal domain associated with lipodystrophy and metabolic alterations [8].
• c.1446A>G (nonstop mutation): Eliminates the stop codon, producing a C-terminally extended protein with residual activity [5].

4.2 Genotype-Phenotype Correlations

The clinical severity of MNGIE correlates with residual TP enzyme activity. Mutations that completely abolish catalytic activity (e.g., nonsense, frameshift, large deletions) typically cause early-onset MNGIE (before age 20) with rapid progression and death by the fourth decade [7, 9]. In contrast, missense mutations that retain 5–30% of wild-type activity are associated with late-onset MNGIE (after age 40) with milder gastrointestinal symptoms and slower neurological decline [2, 3]. Ronchi et al. described patients with biallelic TYMP variants presenting with late-onset mitochondrial myopathy without overt gastrointestinal involvement, expanding the phenotypic spectrum [2]. Similarly, the p.Arg393_Val400dup variant causes a predominantly lipodystrophic phenotype with insulin-resistant diabetes, highlighting the metabolic consequences of partial TP deficiency [4, 8].

4.3 Clinical Features and Diagnostic Criteria

MNGIE is characterized by the classic tetrad of:

1. Gastrointestinal dysmotility: Recurrent nausea, vomiting, abdominal pain, diarrhea, and pseudo-obstruction; leads to severe cachexia [1, 5, 6].
2. Neurological involvement: Peripheral neuropathy (sensorimotor axonal), leukoencephalopathy on brain MRI, and myopathy [1, 6].
3. Ophthalmological signs: Ptosis and progressive external ophthalmoplegia [7].
4. Systemic manifestations: Hearing loss, growth hormone deficiency, and lipodystrophy [1, 8, 9].

The diagnosis is confirmed by plasma thymidine and deoxyuridine levels (elevated >3-fold) and reduced TP enzyme activity in peripheral blood leukocytes (<10% of normal) [3, 7]. Genetic testing for biallelic TYMP mutations is definitive [2, 5].

4.4 Differential Diagnosis

MNGIE must be distinguished from other mitochondrial disorders with overlapping features:

• POLG-related disorders: Mutations in POLG (mitochondrial DNA polymerase gamma) can cause an MNGIE-like phenotype with gastrointestinal dysmotility and leukoencephalopathy, but typically present with additional features such as epilepsy and liver disease [3, 4, 5].
• LIG3-related MNGIE: Biallelic LIG3 mutations cause a novel form of MNGIE with mtDNA depletion, highlighting genetic heterogeneity [5].
• Mitochondrial DNA depletion syndrome 1 (MTDPS1): Caused by TYMP mutations and considered synonymous with MNGIE; however, some patients present with premature ovarian insufficiency as the initial manifestation [9].
• Wernicke encephalopathy: Can complicate MNGIE due to thiamine deficiency from chronic malnutrition, requiring prompt recognition and treatment [3].

4.5 Case Series and Novel Mutations

Recent case series have expanded the mutational spectrum of TYMP:

• Mojtabavi et al. reported two Iranian siblings with novel compound heterozygous mutations (p.Leu148Pro and p.Thr151Pro) presenting with classic MNGIE [5].
• Shah et al. described a Pakistani patient with a homozygous splice-site mutation (c.457+1G>A) and severe early-onset disease [1].
• Jiang et al. identified a novel nonsense mutation (p.Tyr211X) in a Chinese patient with MNGIE and multiple intracranial hemorrhages on brain MRI, an unusual complication [6].
• Xu et al. performed a comprehensive clinical-genetic analysis of Chinese MNGIE patients, identifying 12 novel variants and establishing genotype-phenotype correlations [2].
• Bardakov et al. reported a 40-year-old Russian patient with a novel missense mutation (p.Gly145Arg) and detailed 13-year follow-up, documenting progressive leukoencephalopathy and cachexia [6].

5. Host-Pathogen & Viral Interactions

5.1 SARS-CoV-2 and Thrombosis

TYMP has emerged as a critical mediator of COVID-19-associated thrombosis. Roytenberg et al. demonstrated that the SARS-CoV-2 spike protein (SP) upregulates TYMP expression in endothelial cells and platelets via the NF-κB pathway [5]. TP activity promotes platelet activation and thrombus formation by generating 2-deoxyribose, which enhances the expression of tissue factor and P-selectin. In K18-hACE2 transgenic mice, SP administration increased TP expression and induced pulmonary thrombosis; treatment with the TP inhibitor TPI (7-deazaxanthine) attenuated thrombus formation and improved survival [5]. These findings suggest that TYMP is a potential therapeutic target for COVID-19-associated coagulopathy.

5.2 HIV-1 and Macrophage Activation

Early studies demonstrated that HIV-1 infection of primary human macrophages induces the expression of TNF-α and IL-1β, and TYMP is co-induced in this inflammatory response [4]. TP expression in HIV-infected macrophages may contribute to the chronic inflammation and cardiovascular risk observed in people living with HIV, although direct mechanistic studies are lacking.

5.3 Mycobacterium tuberculosis

Gene expression profiling of tuberculous meningitis (TBM) co-infected with HIV identified TYMP as one of the differentially expressed genes in the cerebrospinal fluid [6]. TP upregulation in TBM may reflect macrophage activation and the angiogenic response to granuloma formation, but its precise role in host defense against mycobacteria remains to be elucidated.

5.4 Viral Oncolysis and Suicide Gene Therapy

The enzymatic activity of TP has been exploited for suicide gene therapy in cancer. The prodrug 5′-deoxy-5-fluorouridine (5′-DFUR) is converted by TP to the active cytotoxic agent 5-fluorouracil (5-FU). In a murine model of MNGIE, López-Estévez et al. demonstrated that TP gene transfer into tumor cells confers sensitivity to 5′-DFUR, resulting in tumor regression [7]. This approach combines the therapeutic benefit of TP expression (restoring nucleoside homeostasis) with a suicide gene strategy for cancer treatment [7].

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 TYMP as a Determinant of Fluoropyrimidine Response

TYMP is the rate-limiting enzyme in the activation of the oral prodrug capecitabine, which is converted to 5-FU via a three-step enzymatic cascade: capecitabine → 5′-deoxy-5-fluorocytidine (via carboxylesterase) → 5′-deoxy-5-fluorouridine (via cytidine deaminase) → 5-FU (via TYMP) [5, 6, 7]. High TYMP expression in tumor tissue is associated with improved response to capecitabine-based chemotherapy, as it enhances intratumoral 5-FU concentrations [4, 5, 7]. Conversely, low TYMP expression predicts resistance.

Pharmacogenetic studies have identified several TYMP polymorphisms that influence treatment outcomes:

• rs11479 (c.1218G>A, p.Val406Val): A synonymous SNP in exon 10 that is associated with improved disease-free survival in colorectal cancer patients receiving capecitabine-based adjuvant chemotherapy [5, 7]. The mechanism is unclear but may involve altered mRNA stability or splicing efficiency.
• rs4706035 (c.1410C>T): Associated with reduced TYMP expression and worse outcomes in rectal cancer patients treated with fluoropyrimidine-based chemoradiotherapy [6].
• rs13170556 (intronic): Linked to differential TYMP expression in breast cancer and response to capecitabine [8].

6.2 TYMP Inhibitors

Several small-molecule inhibitors of TP have been developed, primarily for anti-angiogenic and anti-inflammatory applications:

• TPI (7-deazaxanthine): A potent competitive inhibitor of TP with a Ki of ~0.3 μM. TPI inhibits angiogenesis in vitro and in vivo and reduces tumor growth in xenograft models [5, 8]. It is currently in preclinical development for cancer and COVID-19-associated thrombosis.
• KIN59 (5′-O-tritylinosine): A non-competitive inhibitor that binds to an allosteric site on TP, blocking substrate access [8].
• TP-1 (6-amino-5-bromouracil): A pyrimidine analog that inhibits TP with moderate potency [8].

These inhibitors have shown promise in preclinical models of rheumatoid arthritis, where they reduce synovial inflammation and joint destruction [2, 9].

6.3 Enzyme Replacement Therapy

Erythrocyte-encapsulated thymidine phosphorylase (EE-TP) is an investigational enzyme replacement therapy for MNGIE. In this approach, autologous erythrocytes are loaded with recombinant TP and infused into patients, providing a continuous source of enzyme activity in the circulation [1, 2, 9]. A phase II clinical trial demonstrated that EE-TP treatment significantly reduced plasma thymidine and deoxyuridine levels, improved gastrointestinal symptoms, and stabilized neurological function in MNGIE patients [1, 2]. The therapy is generally well-tolerated, with no serious adverse events reported [1].

6.4 Gene Therapy

Gene therapy is the most promising curative approach for MNGIE. Preclinical studies have evaluated multiple delivery strategies:

• Liver-targeted AAV vectors: Adeno-associated virus (AAV) vectors encoding TYMP under the control of liver-specific promoters (e.g., alpha-1-antitrypsin, thyroxine-binding globulin) have been shown to restore TP activity and normalize nucleoside levels in the Tymp/Upp1 double-knockout (dKO) mouse model of MNGIE [1, 2, 9]. Long-term studies demonstrated sustained metabolic correction for up to 2 years [2, 9]. AAV8-mediated gene therapy has also been tested on ex situ normothermic machine perfusion of human donor livers, demonstrating feasibility for clinical translation [3].
• Hematopoietic stem cell (HSC) gene therapy: Lentiviral vectors encoding TYMP under the control of a myeloid-specific promoter have been used to transduce HSCs, which then differentiate into TP-expressing macrophages that secrete the enzyme into the circulation [4, 5, 6]. This approach achieved long-term metabolic correction in dKO mice and is being evaluated in clinical trials [4, 5].
• Gene editing: CRISPR/Cas9-mediated integration of a TYMP transgene into the albumin locus of hepatocytes has been demonstrated in mice, providing a permanent source of TP expression [7, 8].

6.5 Hematopoietic Stem Cell Transplantation

Allogeneic HSC transplantation (HSCT) is currently the only clinically established treatment for MNGIE that can restore TP activity. By replacing the patient's hematopoietic system with donor-derived TP-expressing cells, HSCT provides a continuous source of enzyme [9]. Reduced-toxicity conditioning regimens have improved the safety profile of HSCT, and successful engraftment leads to normalization of plasma nucleosides and clinical improvement [9]. However, HSCT carries significant risks of graft-versus-host disease and transplant-related mortality, particularly in patients with advanced disease [3, 7].

6.6 Nutritional and Metabolic Support

Nutritional therapy is an essential adjunct in MNGIE management. Patients often require parenteral nutrition due to severe gastrointestinal dysmotility and malabsorption [5]. Wang et al. reported a patient with homozygous TYMP mutation who was maintained on long-term parenteral nutrition, resulting in weight stabilization and improved quality of life [5]. Additionally, coenzyme Q10 and B-vitamin supplementation (particularly thiamine) may provide symptomatic benefit, although evidence is limited [3, 8].

7. Bioinformatic Resources & Database Accessions

Related Clinical & Scientific Guides

• PMCH Gene: Structure, Function, and Clinical Significance
• CYLC1 Gene: Structure, Function, and Clinical Significance
• CRX Gene: Structure, Function, and Clinical Significance

References

[1] Shah S, Shakeel H, Ul Hassan W. Rare pathogenic mutation in the thymidine phosphorylase gene (TYMP) causing mitochondrial neurogastrointestinal encephalomyelopathy. BMJ Neurology Open. 2022. https://www.semanticscholar.org/paper/719d6ff90e8d728af32e06b838fcee9e9b915d97

[2] Sifeddine N, Elkhattabi L, Ait El Cadi C, et al. Insights from the SNP analysis of TYMP gene linking MNGIE. Bioinformation. 2024. https://www.semanticscholar.org/paper/b4d4119ace0d0e80e352dd6ca72ee10f4c9b9402

[3] Mojtabavi H, Fatehi F, Shahkarami S, et al. Novel Mutations of the TYMP Gene in Mitochondrial Neurogastrointestinal Encephalomyopathy: Case Series and Literature Review. Journal of Molecular Neuroscience. 2021. https://www.semanticscholar.org/paper/fda1d433ec4b91f28e0d96d6fa2563a8a7e0f5ed

[4] Bardakov SN, Limaev I, Emelin AM, et al. A new mutation in the TYMP-gene: clinical and morphological characteristics of a patient with MNGIE syndrome. Neuromuscular Diseases. 2022. https://www.semanticscholar.org/paper/780373ad0ad2640a67e1aa50716b2d8300ffe9ba

[5] Jiang Z, Zhao B, Shang H, Song W. A novel nonsense mutation in the TYMP gene causing MNGIE with multiple intracranial hemorrhages on brain MRI. Neurological Sciences. 2020. https://www.semanticscholar.org/paper/5236450956dc286451b7813cdff88350b83e375b

[6] Asadi S, Amjadi H, Valizadeh G, Aranian M. Assessment Genetic Mutations in gene TYMP in indicate Mitochondrial Neuro-Gastro-Intestinal Encephalopathy Syndrome. American Journal of Biomedical Science & Research. 2019. https://www.semanticscholar.org/paper/562ee0ab7b2c3dedfebd9c6a082bf795af238099

[7] TYMP Gene. Definitions. 2020. https://www.semanticscholar.org/paper/c4f926b34f83e37b906ee07ca5c9313559c415d0

[8] Wang J, Chen W, Wang F, et al. Nutrition Therapy for Mitochondrial Neurogastrointestinal Encephalopathy with Homozygous Mutation of the TYMP Gene. Clinical Nutrition Research. 2015. https://www.semanticscholar.org/paper/5aa6a19c7786151001bcd5fcbbe7afecb8a6dc51

[9] Guillem V, Hernández-Boluda JC, Gallardo D,